Apply for the Fierce AI Innovation Awards - Submissions close Thursday, June 18

Boehringer Ingelheim

lung cancer
MedTech

Guardant Health nabs FDA test approval for BI's new cancer drug

Boehringer Ingelheim’s Hernexeos has nabbed a companion diagnostic from Guardant Health after the FDA cleared its liquid biopsy test, Guardant360 CDx.
Ben Adams Jun 12, 2026 9:47am
Boehringer Ingelheim ADA2026 BI

ADA: Tolerability questions linger for Boehringer's obesity drug

Jun 8, 2026 4:30am
Berlin Germany Brandenburg Gate
Favicon Fierce Pharma

Lilly, Boehringer slash investment plans in Germany

Jun 3, 2026 3:10pm
Three blocks displaying from left to right a person a handshake and another person

Boehringer makes €407M bet on Immunitas’ inflammatory asset

May 12, 2026 9:57am
obesity overweight weight loss weigh

Boehringer links dual agonist to 16.6% weight loss in phase 3

Apr 28, 2026 4:00am
red and yellow background with scissors

Click cuts staff after commercial deal restructuring

Apr 14, 2026 10:25am